Improving Cervical Cancer Screening and Treatment for Women Using HPV Self-Sampling and Mobile Health Support in Kenya

What this Trial Is About

This research aims to evaluate a multi-component care strategy called DADA LINK to improve cervical cancer screening and treatment connection among women aged 25 to 49 years in Kenya. The highest rates of cervical cancer occur in sub-Saharan Africa, with it being the leading cause of cancer death among Kenyan women. This study focuses on overcoming barriers at the patient, provider, and facility levels by using tailored strategies based on earlier research and clinic assessments in Nairobi County. The trial compares clinics using the DADA LINK integrated care package, which includes HPV self-sampling kits, care navigation by trained non-physician staff, and use of a mobile health platform called WEMA, against clinics continuing usual care practices. Care coordinators at intervention clinics motivate staff to follow cervical cancer care guidelines, collect patient exit survey data, and manage screening and treatment tracking through the WEMA app. The study lasts 12 months, with an additional 6-month follow-up to assess costs and maintenance of the care strategies. Participants cervical cancer screening and treatment data will be collected from clinic records by study staff. Researchers will measure how many women complete screening during clinic visits and how many receive follow-up triage or treatment within 12 months. The WEMA system also supports communication with patients via text messages to improve attendance. This comprehensive monitoring aims to assess both the implementation and effectiveness of the care package over the study period.

Accelerating Adoption of Patient-centered Cervical Cancer Screening and Treatment Linkage in Kenya